EMRELIS vs KEYTRUDA

Independent side-by-side comparison.

Rated against independent regulatory sources·Last updated October 10, 2026·How we rate

Possible drug interaction. EMRELIS and KEYTRUDA are different prescription medicines. Combining or switching between them can cause interactions — talk to a pharmacist or prescriber before making changes. This page is not medical advice.

Attribute	EMRELIS	KEYTRUDA
Rating	72/100	72/100
Pharmacy pays	—	—
Type	RX	RX
Active ingredient	TELISOTUZUMAB VEDOTIN-TLLV	PEMBROLIZUMAB
Manufacturer	Abbvie	Merck Sharp Dohme
Dosage forms	Injectable	Injectable
Drug class	—	Programmed Death Receptor-1 Blocking Antibody
Boxed warning	None	None
Treats	Non-Small-Cell Lung Carcinoma	Malignant Mesothelioma, Biliary Tract Neoplasms, Urinary Bladder Neoplasms

emrelis keytruda

Rating

72/100

Pharmacy pays

—

Type

Active ingredient

TELISOTUZUMAB VEDOTIN-TLLV

PEMBROLIZUMAB

Manufacturer

Abbvie

Merck Sharp Dohme

Dosage forms

Injectable

Drug class

—

Programmed Death Receptor-1 Blocking Antibody

Boxed warning

None

Treats

Non-Small-Cell Lung Carcinoma

Malignant Mesothelioma, Biliary Tract Neoplasms, Urinary Bladder Neoplasms

Frequently asked questions

Which is better-rated, Emrelis or Keytruda?

Emrelis and Keytruda are tied at 3.6 out of 5 by our independent rating.

What is the difference between Emrelis and Keytruda?

Emrelis contains Telisotuzumab Vedotin-Tllv, while Keytruda contains Pembrolizumab — they have different active ingredients.

Ratings are based on FDA regulatory (recall-safety) data. This comparison is for general reference only — not medical advice. Always consult a licensed professional before choosing or switching a medication.